Search
Kangtai Biology Secures Approval for Clinical Trials of Trivalent Influenza Virus Split Vaccine (MDCK Cell)
2025-08-18 /
Read about 0 minute
Author：小编
Kangtai Biology, in collaboration with Lanzhou Bailing Biotechnology Co., Ltd., has recently secured approval from the National Medical Products Administration for clinical trials of their trivalent influenza virus split vaccine produced using MDCK cells. This vaccine is designed to protect individuals aged 3 and above from influenza virus infections. Notably, no such vaccine has yet been authorized for market release in China.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
